Cassava reports preclinical study on simufilam for TSC-related epilepsy

Cassava Sciences (SAVA) reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex, TSC-related epilepsy. Simufilam, a proprietary oral small molecule, demonstrated a beneficial effect on seizure activity with a positive dose response in this model. Importantly, the results are consistent with findings published in Science Translational Medicine1 of prior research conducted with simufilam at Yale School of Medicine in another mouse model. This new research further supports the potential use of simufilam as a novel, first-in-class treatment for TSC-related epilepsy.